Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
Anuja Chatterjee(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Kavita Sail(AbbVie (United States)), Beenish S. Manzoor(AbbVie (United States)), Arliene Ravelo(Dana-Farber Cancer Institute), Venetia Qendri(AbbVie (United States)), Sheila Shapouri(Dana-Farber Cancer Institute), Gijs van de Wetering(Open University of the Netherlands)
Cited by 20
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595